Introduction
============

Chronic obstructive pulmonary disease (COPD) is currently the third most common cause of death in the world.[@b1-copd-11-2075] COPD is a global health concern and a slowly progressive inflammatory disease caused by airflow obstructions.[@b2-copd-11-2075] COPD is not fully reversible and can lead to progressively worsening breathlessness, which affects daily activities and the health-related quality of life.[@b3-copd-11-2075] Many patients with COPD experience multiple conditions (eg, weight loss and skeletal muscle dysfunction)[@b4-copd-11-2075] and comorbidities (eg, cardiovascular disease, osteoporosis, and depression), which are known to influence the mortality and morbidity rates, hospitalization, and health-related quality of life.[@b5-copd-11-2075]

Anthropometric indicators are essential for evaluating malnutrition,[@b6-copd-11-2075] functional decline, and chronic health conditions, which are risk factors for mortality in geriatric assessment.[@b7-copd-11-2075] Body mass index (BMI), mid-arm circumference (MAC), and calf circumference (CC) are accurate indicators of weight change, terminal functional decline, and functional status, respectively.[@b8-copd-11-2075],[@b9-copd-11-2075] The association between an increased mortality risk and low BMI in old age is well established.[@b10-copd-11-2075],[@b11-copd-11-2075] The association between BMI and mortality risk in patients with COPD has been a subject of research interest for decades.[@b12-copd-11-2075] In patients with COPD, independent of other prognostic variables, a mid-thigh muscle cross-sectional area of ≤70 cm^2^ increases the mortality risk fourfold.[@b13-copd-11-2075] In patients with stable COPD, the prognostic influence of the mid-arm muscle area estimated using anthropometric parameters is a more accurate predictor of mortality risk than BMI.[@b14-copd-11-2075] CC can be used to assess muscle mass,[@b15-copd-11-2075] because low muscle mass is more strongly related to mortality risk in adults than is low fat mass.[@b16-copd-11-2075]

Apart from BMI, scant data is available on MAC and CC, all of which are comparable anthropometric predictors of mortality risk in patients with COPD. We therefore examined and compared the associations of anthropometric indicators, namely low BMI, MAC, and CC, with the prediction of mortality risk in patients with COPD in a 3-year follow-up period.

Materials and methods
=====================

Study design and patients
-------------------------

We conducted a cohort study in patients with COPD who were recruited from the pulmonary outpatient unit of a medical center in Northern Taiwan between January 2011 and December 2014. Patients diagnosed with susceptible COPD on the basis of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, were sampled.[@b17-copd-11-2075] Patients with forced expiratory volume in 1 second (FEV~1~)/forced vital capacity \<0.70 confirmed by post-bronchodilator spirometry were eligible for inclusion. Patients with an acute infection or exacerbation were excluded. In total, 104 eligible patients (98 males and six females) agreed to participate. All the patients were ambulatory in stable conditions and were undergoing standard pharmacological treatment for COPD. The study protocol was approved by the Ethics Committee of the Chang-Gung Memorial Hospital, and all the patients provided written informed consent before participation.

Procedures and measurements
---------------------------

Each patient was interviewed face-to-face for recording demographic, lifestyle, and disease-related data. Their weight, height, fat-free mass index (FFMI), MAC, and CC were measured, following which they underwent the pulmonary functional test. We confirmed the patients with COPD and those with with other diseases, including cardiovascular disorder, skeletal muscle dysfunction, metabolic syndrome and diabetes, osteoporosis, anxiety and depression, lung cancer, and so on, according to medical charts. Current medication was recorded from the patients' statement and mortality data were collected from the chart records at the medical center and confirmed through telephonic follow-up.

BMI was calculated as the weight in kilograms divided by the square of their height in meters (kg/m^2^). MAC and CC were measured to the nearest 0.1 cm using a flexible but nonstretch measuring tape.[@b18-copd-11-2075] MAC was measured with a millimeter tape at the midpoint of the nondominant arm, between the olecranon and acromion. CC was measured by wrapping the tape around the widest part of the calf with the patient in a sitting position, left knee raised at a right angle, and the calf uncovered by rolling up the trouser leg. We used the threshold values of the anthropometric cut-off points according to the Mini Nutritional Assessment Taiwan Version-II (BMI \<21 kg/m^2^ for low BMI, MAC\<23.5 cm for low MAC, CC \<30 cm for low CC).[@b19-copd-11-2075]

Body fat percentage was determined through a bioelectrical impedance analysis (BF-800 body fat monitor, Tanita, Tokyo, Japan),[@b6-copd-11-2075] and the FFMI was calculated by subtracting fat mass from the body weight.[@b10-copd-11-2075]

A pulmonary function test was performed using Spirotrac V (Vitalograph Inc, Lenexa, KS, USA) after a 10-minute rest. The most satisfactory (ie, difference within 200 mL or \<5%) of at least three reproducible FEV~1~ and forced vital capacity values were used in the analysis.

Statistical analysis
--------------------

All data were statistically analyzed using SPSS statistics for Windows, version 19.0 (SPSS Inc. Chicago, IL, USA) and Prism5 (GraphPad Software, La Jolla, CA, USA). Descriptive data were expressed as mean ± standard deviation or percentage. Kaplan--Meier survival curves were stratified by BMI, MAC, and CC for analyses. After adjustment for age, smoking habit, and disease severity, Cox regression analyses were performed to evaluate the relative mortality risks among patients with low BMI, MAC, or CC. The Bayesian information criterion (BIC) was used to compare the extent of association between mortality rate and the anthropometric indicators considered in this study. A lower BIC value indicates a higher predictive ability or a stronger association of the indicator with the mortality risk.[@b20-copd-11-2075] Statistical significance was set at 0.05 in all analyses.

Results
=======

[Table 1](#t1-copd-11-2075){ref-type="table"} lists the characteristics of the study patients. The average age was 74.2±6.9 years, and only 5.8% were female patients. Patients' smoking statuses were as follows: 11.5% nonsmokers, 71.2% ex-smokers, and 17.3% smokers. Over one-half of the patients had mild or moderate COPD, approximately one-third (31.7%) exhibited severe COPD, and only 6.7% exhibited very severe COPD; the mean (%) FEV~1~ was 58.4±20.3; over half (55.8%) of patients had one or two comorbidities. In medication treatment, most of the patients had bronchodilator (83.7%) or steroid (81.7%) use. The mean ± standard deviation anthropometric values were as follows: 23.4±3.7 kg/m^2^, BMI; 26.3±3.2 cm, MAC; 32.9±3.1 cm, CC; and 17.6±2.2 kg/m^2^ FFMI.

[Table 2](#t2-copd-11-2075){ref-type="table"} shows the characteristics of patients with COPD stratified by survival; during the 3-year follow-up period, 22 of the 104 patients died. The mean age of the surviving and dead patients was similar (73.8±7.1 vs 75.4±5.9 years, *P*\>0.05). Most surviving and dead patients had a history of smoking. Both FEV~1~ (%) and GOLD stages differed significantly between the surviving and dead patients (61.4±19.5 vs 47.4±19.6, *P*\<0.01). The three indicators (BMI, MAC, and CC) differed significantly between the surviving and dead patients (23.9±3.5 vs 21.6±3.8; 26.8±2.9 vs 24.2±3.7; 33.4±2.9 vs 30.9±3.8, respectively, all *P*\<0.01). Some factors had no significant differences between the surviving and dead patients, including FFMI that did not differ significantly between the surviving and dead patients (17.8±1.9 vs 16.9±3.2, *P*\>0.05), comorbidities coexistence, bronchodilator, and steroid use (all *P*\>0.05).

[Figure 1](#f1-copd-11-2075){ref-type="fig"} shows the 3-year follow-up Kaplan--Meier survival curves stratified by BMI, MAC, and CC. The survival rates of the patients with low BMI (\<21 kg/m^2^), low MAC (\<23.5 cm), or low CC (\<30 cm) revealed a significantly high mortality during the 3-year follow-up period.

[Table 3](#t3-copd-11-2075){ref-type="table"} shows the hazard ratios and 95% confidence intervals based on the multivariate Cox regression analysis and the BIC value for the predictors of the mortality in patients with COPD. All the models were adjusted for age, smoking status, and disease severity (FEV~1~, % predicted). FEV~1~ was a significant factor on mortality risk in models I, II, and III respectively. A low BMI (\<21 kg/m^2^) was significantly associated with a higher risk of mortality (Hazard ratio \[HR\]=2.8, *P*\<0.05). In model II, a low MAC (\<23.5 cm) was positively associated with a 3.0-fold increase in the mortality risk (*P*\<0.05), whereas in model III, a low CC (\<30 cm) was positively associated with an approximately 4.5-fold increase in mortality (*P*\<0.01). Moreover, age or smoking status was not significantly associated with mortality in these three models. The differences in the BIC values between models III and I, III and II, and II and I were 4.9, 3.33, and 1.58, respectively.

Discussion
==========

In this study, we evaluated the predictive association between the anthropometric indicators and mortality risk in patients with COPD. The results suggest that the three anthropometric variables considered in this study can predict the long-term follow-up mortality in patients with COPD. When stratified by the cut-off points, low CC and low MAC were more effective predictors than was low BMI, showing significantly higher mortality risk during the 3-year follow-up period compared with that associated with normal CC, MAC, and BMI.

Many factors, such as aging, physical activity, nutrition, and chronic health disease, influence anthropometric indicators.[@b21-copd-11-2075] Tsai et al[@b19-copd-11-2075] demonstrated that low CC (\<30 cm in males and \<27 cm in females) and low MAC (\<23.5 cm in males and \<22 cm in females) were more effective than was low BMI (\<21 kg/m^2^) in predicting the follow-up mortality risk in patients aged 65--74 years. However, low CC and low BMI were more effective than low MAC was in patients \>75 years, and low BMI was more effective than low MAC or low CC was in Taiwanese patients aged 53--64 years. Advanced aging is often accompanied by unplanned weight loss and body protein loss.[@b22-copd-11-2075] In the current study, MAC and CC were more accurate predictors of health status and mortality risk in the institutionalized older Taiwanese people than was BMI.[@b8-copd-11-2075] The average age of the patients in our study was 74.2 years, and our results are consistent with those of Tsai et al,[@b19-copd-11-2075] where low CC and low MAC were more effective predictors of 3-year follow-up mortality risk than was low BMI after adjustment for age, smoking status, and disease severity.

The association between increased mortality and low BMI in old age is well established.[@b10-copd-11-2075],[@b11-copd-11-2075] No consensus exists on the causality of this association among patients with COPD.[@b23-copd-11-2075] Apart from BMI, low MAC[@b14-copd-11-2075] and low CC[@b24-copd-11-2075] have been recommended as alternative and more accurate predictors of mortality in older participants[@b25-copd-11-2075] and patients with COPD.[@b14-copd-11-2075] The accuracy of BMI measurement can be low in the older population for such reasons as spinal deformities, difficulties when standing, and fluid retention.[@b25-copd-11-2075] BMI and the cause-specific mortality risk were adjusted for age, sex, and smoking status.[@b23-copd-11-2075] The degree of functional impairment between the upper and lower limbs differs among patients with COPD. Lower limb muscles appear to be associated with muscle endurance and daily functional performance, whereas upper limb muscles have been correlated with both physical and pulmonary functional indicators.[@b26-copd-11-2075] Raftery (1995) suggested that a lower BIC value of 2--6 is a positive evidence for a model.[@b20-copd-11-2075] Because the differences in BIC values between the model with CC and the model with BMI were 4.9, the results of the present study indicated that CC had a stronger association with mortality rate in patients with COPD.

FEV~1~ is an important factor associated with mortality in our study. Esteban et al also found that FEV~1~ was the main predictor of mortality among patients with stable COPD.[@b27-copd-11-2075] We also found that patients rated as GOLD stage I--II (69.5%) have higher survival rate than GOLD stage III--IV (30.5%). Mattila et al demonstrated a strong association between the severity of the GOLD stage and mortality risk in a follow-up study.[@b2-copd-11-2075] FEV~1~ is the most crucial physiologic indicator of the severity of airflow obstruction in COPD.[@b28-copd-11-2075] Although, no single physiological survey has captured multiple factors that elevate the mortality in patients with COPD, a low FEV~1~ has a long-existing association with increased mortality.[@b29-copd-11-2075]

The results of the present study indicated that among the investigated indicators, CC has the highest accuracy for predicting mortality in patients with COPD. Measurement of CC is easy, inexpensive, and noninvasive.

Limitation of the study
-----------------------

This study has a few limitations. First, the study sample was small and drawn from one hospital, which may have led to some bias during sample selection and therefore might not represent the entire spectrum of patients with COPD; this prevented us from conducting a subgroup analysis. Second, our results were based on data analyses obtained mainly from male patients, and the applicability of the study results to female patients requires additional investigations. Third, the influence of some COPD symptoms, such as dyspnea symptoms, exercising tolerance was not considered. Because patients with an acute infection or exacerbation were excluded, the data of acute exacerbation were not analyzed in the present study. In the future, we may use cluster analysis to predict mortality risks in patients with COPD.

Conclusion
==========

Three anthropometric indicators, namely BMI, MAC, and CC, can predict long-term follow-up mortality risk in patients with COPD, among which CC is the most accurate, followed by MAC and BMI.
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![Three-year follow-up survival curves stratified by BMI, MAC, and CC.\
**Notes:** (**A**) The Kaplan--Meier survival curve based on BMI obtained using the log-rank test (Mantel--Cox) *P*\<0.001. (**B**) The Kaplan--Meier survival curve based on MAC obtained using the log-rank test (Mantel--Cox) *P*=0.001. (**C**) The Kaplan--Meier survival curve based on CC obtained using the log-rank test (Mantel--Cox) *P*=0.001.\
**Abbreviations:** BMI, body mass index; CC, calf circumference; MAC, mid-arm circumference.](copd-11-2075Fig1){#f1-copd-11-2075}

###### 

Characteristics of patients with COPD (n=104)

  Variables                                                 n (%)       Mean (SD)
  --------------------------------------------------------- ----------- -----------
  Age, years                                                            74.2±6.9
  Sex                                                                   
   Male                                                     98 (94.2)   
   Female                                                   6 (5.8)     
  Smoking status                                                        
   Nonsmokers                                               12 (11.5)   
   Ex-smokers                                               74 (71.2)   
   Smokers                                                  18 (17.3)   
  GOLD stage[\*](#tfn1-copd-11-2075){ref-type="table-fn"}               
   I                                                        13 (12.5)   
   II                                                       51 (49.0)   
   III                                                      33 (31.7)   
   IV                                                       7 (6.7)     
  FVC, % predicted                                                      76.4±18.9
  FEV~1~, % predicted                                                   58.4±20.3
  Comorbidity                                                           
   No                                                       46 (44.2)   
   Yes                                                      58 (55.8)   
  Medication treatment                                                  
   Bronchodilator use                                       87 (83.7)   
   Steroid use                                              85 (81.7)   
  Anthropometrics                                                       
   BMI (kg/m^2^)                                                        23.4±3.7
   Mid-arm circumference (cm)                                           26.3±3.2
   Calf-circumference (cm)                                              32.9±3.2
   Fat-free mass index (kg/m^2^)                                        17.6±2.2

**Notes:**

GOLD stage I, FEV~1~ ≥80% predicted; II, \<80% FEV~1~ ≤50% predicted; III, \<50% FEV~1~ ≤30% predicted; IV, FEV~1~ \<30%.

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation.

###### 

Characteristics of patients with COPD stratified by survival (n=104)

  Variables              Survived (n=82)   Died[\*](#tfn3-copd-11-2075){ref-type="table-fn"} (n=22)   *P*-value
  ---------------------- ----------------- ---------------------------------------------------------- -----------
  Age, years             73.8±7.1          75.4±5.9                                                   0.360
  Smoking status                                                                                      0.435
   Nonsmokers (n, %)     10 (12.2)         2 (9.1)                                                    
   Ex-smokers (n, %)     58 (70.7)         16 (72.7)                                                  
   Smokers (n, %)        14 (17.1)         4 (18.2)                                                   
  FEV~1~ (% predicted)   61.4±19.5         47.4±19.6                                                  0.004
  COPD severity (n, %)                                                                                0.002
   GOLD stage I/II       57 (69.5)         7 (31.8)                                                   
   GOLD stage III/IV     25 (30.5)         15 (68.2)                                                  
  Comorbidity                                                                                         0.542
   No                    46 (44.2)         12 (11.5)                                                  
   Yes                   36 (34.6)         10 (9.6)                                                   
  Bronchodilator use                                                                                  0.246
   No                    15 (18.3)         2 (9.1)                                                    
   Yes                   67 (81.7)         20 (90.9)                                                  
  Steroid use                                                                                         0.174
   No                    17 (20.7)         2 (9.1)                                                    
   Yes                   65 (79.3)         20 (90.9)                                                  
  Anthropometrics                                                                                     
   BMI (kg/m^2^)         23.9± 3.5         21.6±3.8                                                   0.008
   MAC (cm)              26.8±2.9          24.2±3.7                                                   0.001
   CC (cm)               33.4±2.9          30.9±3.8                                                   0.001
   FFMI (kg/m^2^)        17.8±1.9          16.9±3.2                                                   0.077

**Note:**

Died: GOLD stage I (n=3), II (n=4), III (n=12), IV (n=3).

**Abbreviations:** BMI, body mass index; CC, calf-circumference; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume 1; FFMI, fat-free mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MAC, mid-arm circumference.

###### 

Predictors of mortality in patients with COPD based on multivariate Cox regression and the BIC

  Variables            Model I              Model II   Model III                                         
  -------------------- -------------------- ---------- -------------------- ------- -------------------- -------
  Age (years)                                                                                            
   \<64                1                    0.470      1                    0.481                        0.279
   65--74              3.68 (0.45, 30.01)   0.223      3.56 (0.44, 28.76)   0.233   4.75 (0.56, 40.55)   0.154
   ≥75                 3.64 (0.42, 31.55)   0.242      3.59 (0.42, 30.83)   0.243   6.16 (0.66, 57.38)   0.111
  Smoking status                                                                                         
   Nonsmokers          1                    0.657      1                    0.772   1                    0.700
   Ex-smokers          1.12 (0.13, 9.48)    0.915      1.48 (0.18, 11.94)   0.712   0.93 (0.11, 7.97)    0.944
   Smokers             1.79 (0.20, 15.94)   0.600      1.98 (0.23, 17.25)   0.536   1.46 (0.16, 13.19)   0.737
  FEV~1~ (%)           0.97 (0.94, 1.00)    0.033      0.97 (0.94, 0.99)    0.012   0.96 (0.93, 0.99)    0.004
  BMI (\<21 kg/m^2^)   2.78 (1.10, 7.10)    0.031      NA                           NA                   
  MAC (\<23.5 cm)      NA                              3.09 (1.30, 7.38)    0.011   NA                   
  CC (\<30 cm)         NA                              NA                           4.40 (1.82, 10.63)   0.001

**Notes:** Model I: −2 likelihood log =182.21; adjusted for age, smoking status, FEV~1~% (pred), BMI; BIC =−268.30. Model II: −2 likelihood log =180.63; adjusted for age, smoking status, FEV~1~% (pred), MAC; BIC =−269.88. Model III: −2 likelihood log =177.30; adjusted for age, smoking status, FEV~1~% (pred), CC; BIC =−273.21. Model I BIC difference Model II =1.58; Model I BIC difference Model III =4.91; Model II BIC difference Model III =3.33.

**Abbreviations:** BIC, Bayesian information criterion; BMI, body mass index; CC, calf-circumference; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume 1; HR, hazard ratio; MAC, mid-arm circumference; NA, not applicable.
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